Page last updated: 2024-09-03
(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine and Vomiting
(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine has been researched along with Vomiting in 2 studies
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Armour, DR; Bays, DE; Evans, B; Giblin, GM; Heron, N; Hubbard, T; Liang, K; Middlemiss, D; Mordaunt, J; Ward, P | 1 |
Bountra, C; Dale, TJ; Gale, JD; Gardner, CJ; Jordan, CC; Kilpatrick, GJ; Twissell, DJ; Ward, P | 1 |
Other Studies
2 other study(ies) available for (2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine and Vomiting
Article | Year |
---|---|
Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity.
Topics: Animals; Antiemetics; Biological Availability; Cell Membrane; CHO Cells; Cricetinae; Dogs; Female; Ferrets; Gerbillinae; Magnetic Resonance Spectroscopy; Male; Neurokinin-1 Receptor Antagonists; Piperidines; Tachykinins; Tetrazoles; Vomiting; Whole-Body Irradiation | 1995 |
The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040.
Topics: Animals; Antiemetics; Dogs; Dose-Response Relationship, Drug; Emetics; Ferrets; Male; Motion Sickness; Neurokinin-1 Receptor Antagonists; Piperidines; Radiation Injuries, Experimental; Shrews; Tetrazoles; Vomiting | 1995 |